Diabetes and Glucose Metabolism in Thalassemia Major: An Update

References

• Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2-star (T2*) MR for the early diagnosis of myocardial iron overload. Eur Heart J. 2001;22:2171–2179.
   PubMed Web of Science ®Google Scholar
• Wood JC, Ghugre N. Magnetic resonance imaging assessment of excess iron in thalassemia, sickle cell disease and other iron overload diseases. Hemoglobin. 2008;32:85–96.
   PubMed Web of Science ®Google Scholar
• De Sanctis V, Eleftheriou A, Malaventura C. Thalassaemia international federation study group on growth and endocrine complications in thalassaemia. Prevalence of endocrine complications and short stature in patients with thalassaemia major: a multicenter study by the thalassaemia international federation (TIF). Pediatr Endocrinol Rev. 2004;2(Suppl 2):249–255.
   PubMedGoogle Scholar
• Toumba M, Sergis A, Kanaris C, et al. Endocrine complications in patients with thalassaemia major. Pediatr Endocrinol Rev. 2007;5:642–648.
   PubMedGoogle Scholar
• Hafez M, Youssry I, El-Hamed FA, et al., et al. Abnormal glucose tolerance in beta thalassemia: assessment of risk factors. Hemoglobin. 2009;33:101–108.
   PubMed Web of Science ®Google Scholar
• Gamberini MR, Fortini M, De Sanctis V, et al., al Diabetes mellitus and impaired glucose tolerance in thalassaemia major: incidence, prevalence, risk factors and survival in patients followed in the Ferrara center. Pediatr Endocrinol Rev. 2004;2(Suppl 2):285–291.
   PubMedGoogle Scholar
• Jaruratanasirikul S, Chareonmuang R, Wongcharnchailert M, et al. Prevalence of impaired glucose metabolism in beta-thalassemic children receiving hypertransfusions with a suboptimal dosage of iron-chelating therapy. Eur J Pediatr. 2008;167:873–876.
   PubMed Web of Science ®Google Scholar
• Kattamis C, Ladis V, Tsoussis D, et al. Evolution of glucose intolerance and diabetes in transfused patients with thalassemia. Pediatr Endocrinol Rev. 2004;2(Suppl 2):267–271.
   PubMedGoogle Scholar
• Soliman A, De Sanctis V, Yassin M, et al., Continuous glucose monitoring system and new era of early diagnosis of diabetes in high risk groups. Indian J Endocrinol Metab. 2014;18:274–282.
   PubMedGoogle Scholar
• De Sanctis V, Soliman A, Yassin M. Iron overload and glucose metabolism in subjects with β-thalassaemia major: an overview. Curr Diabetes Rev. 2013;9:332–341.
   PubMedGoogle Scholar
• Li M-J, Peng SS, Lu M-Y, et al., Diabetes mellitus in patients with thalassemia major. Pediatr Blood Cancer. 2014;61:20–24.
   PubMed Web of Science ®Google Scholar
• Tzoulis P. Review of endocrine complications in adult patients with β-thalassaemia major. Thalassemia Rep. 2014;4:51–56.
   Google Scholar
• Ang AL, Tzoulis P, Prescott E, et al., History of myocardial iron loading is a strong risk factor for diabetes mellitus and hypogonadism in adults with β thalassemia major. Eur J Haematol. 2014;92:229–236.
   PubMed Web of Science ®Google Scholar
• Pepe A, Meloni A, Rossi G, et al., Cardiac complications and diabetes in thalassaemia major: a large historical multicentre study. Br J Haematol. 2013;163:520–527.
   PubMed Web of Science ®Google Scholar
• Noetzli LJ, Mittelman SD, Watanabe RM, et al., Pancreatic iron and glucose dysregulation in thalassemia major. Am J Hematol. 2012;87:155–160.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes-2015. Diabetes Care. 2015;38(Suppl 1):S8–S16.
   PubMed Web of Science ®Google Scholar
• Albaker WI, Yousef AA, Khamis AH, et al. The continuous glucose monitoring system (CGMS) in patients with beta-thalassemia major. Saudi J Med Med Sci. 2013;1:88–93.
   Google Scholar
• Choudhary A, Giardina P, Antal Z, et al. Unreliable oral glucose tolerance test and haemoglobin A1C in beta thalassaemia major - a case for continuous glucose monitoring? Br J Haematol. 2013;162:132–135.
   PubMed Web of Science ®Google Scholar
• Mooy JM, Grootenhuis PA, De Vries H, et al. Intra-individual variation of glucose, specific insulin and proinsulin concentrations measured by two oral glucose tolerance tests in a general Caucasian population: The Hoorn study. Diabetologia. 1996;39:298–305.
   PubMed Web of Science ®Google Scholar
• Tahara Y, Shima K. Kinetics of HbA1c, glycated albumin, and fructosamine and analysis of their weight functions against preceding plasma glucose level. Diabetes Care. 1995;18:440–447.
   PubMed Web of Science ®Google Scholar
• Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 1997;20:1183–1197.
   PubMed Web of Science ®Google Scholar
• Kattamis C, Delaporta P, Dracopoulou M, et al.Credibility of HbA1c in diagnosis and management of disturbances of glucose and diabetes in trabsfused patients with thalassemia. Riv Ital Med Adolesc. 2014;12:65–71.
   Google Scholar
• Au W-Y, Lam WW, Chu W, et al. A T2* magnetic resonance imaging study of pancreatic iron overload in thalassemia major. Haematologica. 2008;93:116–119.
   PubMed Web of Science ®Google Scholar
• Bas M, Gumruk F, Gonc N, et al. Biochemical markers of glucose metabolism may be used to estimate the degree and progression of iron overload in the liver and pancreas of patients with β-thalassemia major. Ann Hematol. 2015;94:1099–1104.
   PubMed Web of Science ®Google Scholar
• Jung HJ, Kim YS, Kim SG, et al. The impact of pegylated interferon and ribavirin combination treatment on lipid metabolism and insulin resistance in chronic hepatitis C patients. Clin Mol Hepatol. 2014;20:38–46.
   PubMedGoogle Scholar
• Singh Y, Garg MK, Tandon N, et al. A study of insulin resistance by HOMA-IR and its cut-off value to identify metabolic syndrome in urban Indian adolescents. J Clin Res Pediatr Endocrinol. 2013;5:245–251.
   PubMed Web of Science ®Google Scholar
• Angelopoulos NG, Zervas A, Livadas S, et al., et al. Reduced insulin secretion in normoglycaemic patients with beta-thalassaemia major. Diabet Med. 2006;23:1327–1331.
   PubMed Web of Science ®Google Scholar
• Meyer C, Pimenta W, Woerle HJ, et al. Different mechanisms for impaired fasting glucose and impaired postprandial glucose tolerance in humans. Diabetes Care. 2006;29:1909–1914.
   PubMed Web of Science ®Google Scholar
• Hershko C, Weatherall DJ. Iron-chelating therapy. Crit Rev Clin Lab Sci. 1988;26:303–345.
   PubMed Web of Science ®Google Scholar
• Fernandez-Real JM, Lopez-Bermejo A, Ricart W. Iron stores, blood donation, and insulin sensitivity and secretion. Clin Chem. 2005;51:1201–1205.
   PubMed Web of Science ®Google Scholar
• Walter PB, Fung EB, Killilea DW, et al. Oxidative stress and inflammation in iron overloaded patients with beta-thalassaemia or sickle cell disease. Br J Haematol. 2006;135:254–263.
   PubMed Web of Science ®Google Scholar
• Monge L, Pinach S, Caramellino L, et al. The possible role of autoimmunity in the pathogenesis of diabetes in B-thalassemia major. Diabetes Metab. 2001;27(2 Pt 1):149–154.
   PubMed Web of Science ®Google Scholar
• Dehshal MH, Hooghooghi AH, Kebryaeezadeh A, et al. Zinc deficiency aggravates abnormal glucose metabolism in thalassemia major patients. Med Sci Monit. 2007;13:235–239.
   Google Scholar
• Fung EB, Gildengorin G, Talwar S, et al. Zinc status affects glucose homeostasis and insulin secretion in patients with thalassemia. Nutrients. 2015;7:4296–4307.
   PubMed Web of Science ®Google Scholar
• Midiri M, Lo Casto A, Sparacia G, et al. MR imaging of pancreatic changes in patients with transfusion-dependent beta-thalassemia major. Am J Roentgenology. 1999;173:187–192.
   PubMed Web of Science ®Google Scholar
• Westwood MA, Wonke B, Maceira AM, et al. Left ventricular diastolic function compared with T2• cardiovascular magnetic resonance for early detection of myocardial iron overload in thalassemia major. J Magn Reson Imaging. 2005;22(2):229–233.
   PubMed Web of Science ®Google Scholar
• Wood JC, Enriquez C, Ghugre N, et al. MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood. 2005;106(4):1460–1465.
   PubMed Web of Science ®Google Scholar
• Tanner MA, Galanello R, Dessi C, et al. Myocardial iron loading in patients with thalassemia major on deferoxamine chelation. J Cardiovasc Magn Reson. 2006;8:543–547.
   PubMed Web of Science ®Google Scholar
• Tanner MA, He T, Westwood MA, et al. Multicenter validation of the transferability of the magnetic resonance T2* technique for the quantification of tissue iron. Haematologica. 2006;91:1388–1391.
   PubMed Web of Science ®Google Scholar
• Kattamis A, Dinopoulos A, Ladis V, et al. Variations of ferritin levels over a period of 15 years as a compliance chelation index in thalassemic patients. Am J Hematol. 2001;68:221–224.
   PubMed Web of Science ®Google Scholar
• Gamberini MR, De Sanctis V, Gilli G, et al. Hypogonadism, diabetes mellitus, hypothyroidism, hypoparathyroidism: incidence and prevalence related to iron overload and chelation therapy in patients with thalassaemia major followed from 1980 to 2007 in the Ferrara centre. Pediatr Endocrinol Rev. 2008;6(Suppl 1):158–169.
   PubMedGoogle Scholar
• Christoforidis A, Perifanis V, Tsatra I, et al. Evolution of OGTT in patients with beta-thalassaemia major in relation to chelation therapy. Diabetes Res Clin Pract. 2007;76:6–11.
   PubMed Web of Science ®Google Scholar
• Farmaki K, Angelopoulos N, Anagnostopoulos G, et al., Effect of enhanced iron chelation therapy on glucose metabolism in patients with betathalassaemia major. Br J Haematol. 2006;134:438–444.
   PubMed Web of Science ®Google Scholar
• Farmaki K, Tzoumari I, Pappa C, et al. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. Br J Haematol. 2010;148:466–475.
   PubMed Web of Science ®Google Scholar
• Cappellini MD, Cohen A, Porter J, et al., editors. Guidelines for the management of transfusion dependent thalassaemia (TDT). 3rd ed. Nicosia (CY): Thalassaemia International Federation; 2014.
   Google Scholar
• Bromage DI, Yellon DM. The pleiotropic effects of metformin: time for prospective studies. Cardiovasc Diabetol. 2015 Aug 14;14:109. doi:10.1186/s12933-015-0273-5.
   PubMed Web of Science ®Google Scholar
• Ladis V, Theodorides C, Palamidou F, et al. Glucose disturbances and regulation with glibenclamide in thalassemia. J Pediatr Endocrinol Metab. 1998;11(Suppl 3):871–878.
   PubMed Web of Science ®Google Scholar
• Mangiagli A, Campisi S, De Sanctis V, et al. Effects of acarbose in beta-thalassaemia major patients with normal glucose tolerance and hyperinsulinism. Pediatr Endocrinol Rev. 2004;2(Suppl 2):272–275.
   PubMedGoogle Scholar
• Mangiagli A, Campisi S, De Sanctis V, et al. Effects of acarbose in patients with beta thalassaemia major and abnormal glucose homeostasis. Pediatr Endocrinol Rev. 2004;2(Suppl 2):276–278.
   PubMedGoogle Scholar
• Dhouib N, Turki Z, Mellouli F, et al. Efficacy of metformin in the treatment of diabetes mellitus complicating thalassemia major. Tunis Med. 2010;88:136.
   PubMedGoogle Scholar
• Konrad D, Daneman D, Kirby M, et al. Cardiac failure after initiation of insulin treatment in diabetic patients with beta-thalassemia major. J Pediatr. 2003;143:541–542.
   PubMed Web of Science ®Google Scholar
• De Sanctis V, Incorvaia C, Soliman AT, et al. Does insulin like growth factor-1 (IGF-1) deficiency have a “protective” role in the development of diabetic retinopathy in thalassamia major patients? Mediterr J Hematol Infect Dis. 2015 May 20;7(1):e2015038. eCollection 2015. doi:10.4084/MJHID.2015.038.
   Google Scholar
• Barnard M, Tzoulis P. Diabetes and thalassaemia. Thalassemia Reports. 2013;3(1s):e18.
   Google Scholar